(MENAFN- EIN Presswire)
Posters feature innovative technologies that address limitations of gene therapy production
LAUSANNE, SWITZERLAND, October 17, 2024 /EINPresswire / -- NewBiologix SA, a
technology innovation company pioneering innovative solutions to enable efficient, cost-effective and large-scale production of
viral vectors for gene therapy, today announced that two abstracts have been selected for presentation at the 31st Annual European Society for Gene & Cell Therapy
congress (ESGCT) , taking place October 22-25, 2024, at La Nuvola in Rome, Italy.
Poster presentation details are as follows:
Generation and Characterization of a HEK293 Cell Line for rAAV production.
Session Name: Poster Session I
Session Date: Tuesday, October 22, 2024
Presentation Time: 19:30 to 21:00 CEST
Room: Concourse Level I & Mezzanine Concourse
Poster ID: P0039
An Integrated Platform for the Analysis and Quality Control of rAAV Vectors Based on Long-Read Sequencing.
Session Name: Poster Session II
Session Date: Wednesday, October 23, 2024
Presentation Time: 13:30 to 15:00 CEST
Room: Concourse Level I & Mezzanine Concourse
Poster ID: P0174
To meet with NewBiologix at ESGCT, reach out to Déborah Ley at ....
About NewBiologix SA
NewBiologix SA is a biotechnology company innovating Swiss-engineered solutions and technologies for cell and gene therapy production. The company brings a specialized focus in this field together with deep expertise in cell line engineering. NewBiologix addresses gene therapy production limitations with its full suite of advanced cell lines for licensing as well as platform-based services. By enabling partners to produce more reliable, safer gene therapies faster and at scale, the company is shaping the future of patient health. Learn more at .
Déborah Ley
Chief Operating Officer
...
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN17102024003118003196ID1108789089
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.